<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2108503</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>05</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>05</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0038-4348</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>83</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1990</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Southern medical journal</Title>
                <ISOAbbreviation>South. Med. J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gentamicin-resistant enterococcal endocarditis: the need for routine screening for high-level resistance to aminoglycosides.</ArticleTitle>
            <Pagination>
                <MedlinePgn>458-60</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We have reported a case of high-level gentamicin-resistant enterococcal endocarditis as a complication of intravenous narcotic abuse. Because routine screening of enterococcal blood isolates for high-level aminoglycoside resistance was not done, the patient possibly received suboptimal therapy. This case amplifies the necessity of a systematic screening program for enterococcal blood isolates to detect high-level resistance to gentamicin and streptomycin in clinical laboratories.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Libertin</LastName>
                    <ForeName>C R</ForeName>
                    <Initials>CR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, University of Illinois, Chicago.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McKinley</LastName>
                    <ForeName>K M</ForeName>
                    <Initials>KM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>South Med J</MedlineTA>
            <NlmUniqueID>0404522</NlmUniqueID>
            <ISSNLinking>0038-4348</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005839">Gentamicins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>70D95007SX</RegistryNumber>
                <NameOfSubstance UI="D003932">Heroin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Y45QSO73OB</RegistryNumber>
                <NameOfSubstance UI="D013307">Streptomycin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004697">Endocarditis, Bacterial</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013293">Enterococcus faecalis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005069">Evaluation Studies as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005839">Gentamicins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D003932">Heroin</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008826">Microbial Sensitivity Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013290">Streptococcal Infections</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013307">Streptomycin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015819">Substance Abuse, Intravenous</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>4</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2108503</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9152303</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>06</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>06</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0022-3476</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>130</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>1997</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of pediatrics</Title>
                <ISOAbbreviation>J. Pediatr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Safety of intravenous ketorolac therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>846</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mofenson</LastName>
                    <ForeName>H C</ForeName>
                    <Initials>HC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caraccio</LastName>
                    <ForeName>T R</ForeName>
                    <Initials>TR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016420">Comment</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Pediatr</MedlineTA>
            <NlmUniqueID>0375410</NlmUniqueID>
            <ISSNLinking>0022-3476</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>D8K2JPN18B</RegistryNumber>
                <NameOfSubstance UI="D014046">Tolmetin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YZI5105V0L</RegistryNumber>
                <NameOfSubstance UI="D020910">Ketorolac</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentOn">
                <RefSource>J Pediatr. 1996 Aug;129(2):292-6</RefSource>
                <PMID Version="1">8765630</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058186">Acute Kidney Injury</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020910">Ketorolac</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014046">Tolmetin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1997</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1997</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1997</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9152303</ArticleId>
            <ArticleId IdType="pii">S0022-3476(97)80042-X</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">5365949</PMID>
        <DateCreated>
            <Year>1970</Year>
            <Month>03</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1970</Year>
            <Month>03</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0022-2593</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1969</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medical genetics</Title>
                <ISOAbbreviation>J. Med. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>An improved and simplified method of detecting the acetylator phenotype.</ArticleTitle>
            <Pagination>
                <MedlinePgn>405-7</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Evans</LastName>
                    <ForeName>D A</ForeName>
                    <Initials>DA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>J Med Genet</MedlineTA>
            <NlmUniqueID>2985087R</NlmUniqueID>
            <ISSNLinking>0022-2593</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>48U51W007F</RegistryNumber>
                <NameOfSubstance UI="D013418">Sulfamethazine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>V83O1VOZ8L</RegistryNumber>
                <NameOfSubstance UI="D007538">Isoniazid</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1965 Nov;150(2):298-304</RefSource>
                <PMID Version="1">5855885</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 1968 Jan-Feb;9(1):80-8</RefSource>
                <PMID Version="1">5638098</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Perspect Biol Med. 1959;2(4):473-517</RefSource>
                <PMID Version="1">13667394</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Tuberc Pneumol Scand. 1963;43:181-95</RefSource>
                <PMID Version="1">14064831</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Lab Clin Med. 1964 Mar;63:394-403</RefSource>
                <PMID Version="1">14164493</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Life Sci. 1965 Jan;4:99-107</RefSource>
                <PMID Version="1">14257074</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br Med J. 1960 Aug 13;2(5197):485-91</RefSource>
                <PMID Version="1">13820968</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005787">Gene Frequency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006261">Headache</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007538">Isoniazid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008722">Methods</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D010641">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013418">Sulfamethazine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000652">urine</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1468783</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1969</Year>
                <Month>12</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1969</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1969</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">5365949</ArticleId>
            <ArticleId IdType="pmc">PMC1468783</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19013687</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>09</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-6760</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>54</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of emergency medicine</Title>
                <ISOAbbreviation>Ann Emerg Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality.</ArticleTitle>
            <Pagination>
                <MedlinePgn>409-20</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.annemergmed.2008.09.023</ELocationID>
            <Abstract>
                <AbstractText Label="STUDY OBJECTIVE" NlmCategory="OBJECTIVE">Cocaine toxicity results in cardiovascular complications, seizures, and death and accounts for approximately 20% of drug-related emergency department visits every year. Presently, there are no treatments to eliminate the toxic effects of cocaine. The present study hypothesizes that a bacterial cocaine esterase with high catalytic efficiency would provide rapid and robust protection from cocaine-induced convulsions, epileptogenic activity, and lethality.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Cocaine-induced paroxysmal activity and convulsions were evaluated in rats surgically implanted with radiotelemetry devices (N=6 per treatment group). Cocaine esterase was administered 1 minute after a lethal dose of cocaine or after cocaine-induced convulsions to determine the ability of the enzyme to prevent or reverse, respectively, the effects of cocaine.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The cocaine esterase prevented all cocaine-induced electroencephalographic changes and lethality. This effect was specific for cocaine because the esterase did not prevent convulsions and death induced by a cocaine analog, (-)-2beta-carbomethoxy-3beta-phenyltropane. The esterase prevented lethality even after cocaine-induced convulsions occurred. In contrast, the short-acting benzodiazepine, midazolam, prevented cocaine-induced convulsions but not the lethal effects of cocaine.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The data showed that cocaine esterase successfully degraded circulating cocaine to prevent lethality and that cocaine-induced convulsions alone are not responsible for the lethal effects of cocaine in this model. Therefore, further investigation into the use of cocaine esterase for treating cocaine overdose and its toxic effects is warranted.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jutkiewicz</LastName>
                    <ForeName>Emily M</ForeName>
                    <Initials>EM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109-0632, USA. ejutkiew@umich.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baladi</LastName>
                    <ForeName>Michelle G</ForeName>
                    <Initials>MG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cooper</LastName>
                    <ForeName>Ziva D</ForeName>
                    <Initials>ZD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Narasimhan</LastName>
                    <ForeName>Diwahar</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sunahara</LastName>
                    <ForeName>Roger K</ForeName>
                    <Initials>RK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Woods</LastName>
                    <ForeName>James H</ForeName>
                    <Initials>JH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DA021416</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DA021416</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DA021416-01</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 DA07268</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Emerg Med</MedlineTA>
            <NlmUniqueID>8002646</NlmUniqueID>
            <ISSNLinking>0196-0644</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>74163-84-1</RegistryNumber>
                <NameOfSubstance UI="C021278">troparil</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.1.-</RegistryNumber>
                <NameOfSubstance UI="D002265">Carboxylic Ester Hydrolases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.1.-</RegistryNumber>
                <NameOfSubstance UI="C019921">cocaine esterase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>R60L0SM5BC</RegistryNumber>
                <NameOfSubstance UI="D008874">Midazolam</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Biochem Behav. 1991 Jul;39(3):625-33</RefSource>
                <PMID Version="1">1784591</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Cardiol. 2007 Sep 15;100(6):1040-3</RefSource>
                <PMID Version="1">17826394</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Alcohol Depend. 1991 Dec 31;29(2):145-51</RefSource>
                <PMID Version="1">1797525</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Struct Biol. 2002 Jan;9(1):17-21</RefSource>
                <PMID Version="1">11742345</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2002 Aug;302(2):710-6</RefSource>
                <PMID Version="1">12130735</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 2002 Oct 15;41(41):12297-307</RefSource>
                <PMID Version="1">12369817</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol Methods. 2002 Nov 1;269(1-2):299-310</RefSource>
                <PMID Version="1">12379369</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Crit Care Med. 2003 Dec;31(12):2794-801</RefSource>
                <PMID Version="1">14668617</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Intensive Care Med. 2004 Jul-Aug;19(4):183-93</RefSource>
                <PMID Version="1">15296619</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Forensic Sci Int. 1978 Sep-Oct;12(2):119-25</RefSource>
                <PMID Version="1">730097</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1983 Jun;225(3):509-14</RefSource>
                <PMID Version="1">6864516</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1989 Oct;251(1):131-41</RefSource>
                <PMID Version="1">2529364</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurology. 1990 Mar;40(3 Pt 1):404-7</RefSource>
                <PMID Version="1">2107459</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Drug Alcohol Abuse. 1990;16(3-4):307-17</RefSource>
                <PMID Version="1">2126913</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Heart J. 1991 Jun;121(6 Pt 1):1639-48</RefSource>
                <PMID Version="1">2035378</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Epilepsia. 1991 Nov-Dec;32(6):890-4</RefSource>
                <PMID Version="1">1743162</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicology. 1991 Fall;12(3):621-6</RefSource>
                <PMID Version="1">1745445</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Emerg Med. 1992 May;21(5):486-93</RefSource>
                <PMID Version="1">1570902</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1992 Sep;262(3):936-46</RefSource>
                <PMID Version="1">1527734</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1993 Mar 26;259(5103):1899-901</RefSource>
                <PMID Version="1">8456315</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Biochem Behav. 1993 Sep;46(1):61-5</RefSource>
                <PMID Version="1">8255923</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Res. 1994 Feb;74(2):281-90</RefSource>
                <PMID Version="1">8293567</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cardiovasc Res. 1994 Jan;28(1):105-11</RefSource>
                <PMID Version="1">8111779</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Stroke. 1994 Mar;25(3):631-8</RefSource>
                <PMID Version="1">8128518</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Emerg Med. 1994 Mar;23(3):494-8</RefSource>
                <PMID Version="1">8135424</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cardiothorac Vasc Anesth. 1995 Jun;9(3):290-6</RefSource>
                <PMID Version="1">7669962</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cardiovasc Pharmacol. 1997 Feb;29(2):145-55</RefSource>
                <PMID Version="1">9057062</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10176-81</RefSource>
                <PMID Version="1">9707620</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 1999 Jan;55(1):83-91</RefSource>
                <PMID Version="1">9882701</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Chem. 1999 Jul 29;42(15):2721-36</RefSource>
                <PMID Version="1">10425082</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pharmacol. 1999 Jul 21;377(2-3):167-73</RefSource>
                <PMID Version="1">10456426</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Forensic Sci Int. 2005 Jun 30;151(1):81-4</RefSource>
                <PMID Version="1">15935945</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2006 Dec;70(6):1885-91</RefSource>
                <PMID Version="1">16968810</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2007 Feb;320(2):926-33</RefSource>
                <PMID Version="1">17114567</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Ann Emerg Med. 2010 May;55(5):484-5; author reply 485-6</RefSource>
                <PMID Version="1">20417385</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001419">Bacteria</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002265">Carboxylic Ester Hydrolases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004569">Electroencephalography</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006993">Hypnotics and Sedatives</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008874">Midazolam</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS367593</OtherID>
        <OtherID Source="NLM">PMC3357128</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>1</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2008</Year>
                <Month>9</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>9</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>9</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0196-0644(08)01787-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.annemergmed.2008.09.023</ArticleId>
            <ArticleId IdType="pubmed">19013687</ArticleId>
            <ArticleId IdType="pmc">PMC3357128</ArticleId>
            <ArticleId IdType="mid">NIHMS367593</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2108509</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>05</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>05</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0040-3709</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>41</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1990</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Teratology</Title>
                <ISOAbbreviation>Teratology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of lithium carbonate on mouse and rat embryos in vitro.</ArticleTitle>
            <Pagination>
                <MedlinePgn>155-60</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Lithium is effective in the treatment of manic-depressive psychosis but is suspected to be a developmental toxicant in humans. It is a developmental toxicant in mice and rats in vivo, but at human therapeutic serum levels of 0.6-1.6 meq/L, rats appear to be more sensitive to the effects of the drug than do mice. The species susceptibility to lithium-induced defects was evaluated by using a rodent whole embryo culture system employing mouse and rat embryos treated at comparable developmental stages. Mouse embryos were cultured on gestational days 8-10, and rat embryos were cultured on gestational days 10-12. Care was taken to insure that all embryos had 10 +/- 2 somite pairs at the beginning of the culture period. Embryos were cultured for 44 hours in rat serum to which lithium was added to attain final drug concentrations of 0.6, 1.2, 1.8, 2.4, or 5.0 meq/L. Control embryos were treated with distilled water, which served as the vehicle. In rats, lithium induced significant decreases in various parameters at 1.8, 2.4, and 5.0 meq/L; no malformations were observed in rats of this stage. In mice, significant decreases occurred at 2.4 and 5.0 meq/L, and embryos treated at the highest concentration had a significantly increased frequency of open neural tubes. Rat embryos were also cultured with lithium on gestational days 9-11. The lowest dose producing developmental toxicity at this stage was 0.6 meq/L. Open neural tubes were present among younger rat embryos; however, this defect occurred in all groups, including the control group.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hansen</LastName>
                    <ForeName>D K</ForeName>
                    <Initials>DK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Food and Drug Administration, Department of Health and Human Services, Jefferson, Arkansas 72079-9502.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Walker</LastName>
                    <ForeName>R C</ForeName>
                    <Initials>RC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grafton</LastName>
                    <ForeName>T F</ForeName>
                    <Initials>TF</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Teratology</MedlineTA>
            <NlmUniqueID>0153257</NlmUniqueID>
            <ISSNLinking>0040-3709</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>2BMD2GNA4V</RegistryNumber>
                <NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9FN79X2M3F</RegistryNumber>
                <NameOfSubstance UI="D008094">Lithium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004622">Embryo, Mammalian</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005314">Embryonic and Fetal Development</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005313">Fetal Death</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D066298">In Vitro Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008094">Lithium</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016651">Lithium Carbonate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009436">Neural Tube Defects</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013045">Species Specificity</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>2</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2108509</ArticleId>
            <ArticleId IdType="doi">10.1002/tera.1420410205</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20058253</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>03</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>06</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1439-7633</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Mar</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chembiochem : a European journal of chemical biology</Title>
                <ISOAbbreviation>Chembiochem</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Unnatural polyketide analogues selectively target the HER signaling pathway in human breast cancer cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>573-80</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cbic.200900674</ELocationID>
            <Abstract>
                <AbstractText>Receptor tyrosine kinases are critical targets for the regulation of cell survival. Cancer patients with abnormal receptor tyrosine kinases (RTK) tend to have more aggressive disease with poor clinical outcomes. As a result, human epidermal growth factor receptor kinases, such as EGFR (HER1), HER2, and HER3, represent important therapeutic targets. Several plant polyphenols including the type III polyketide synthase products (genistein, curcumin, resveratrol, and epigallocatechin-3-galate) possess chemopreventive activity, primarily as a result of RTK inhibition. However, only a small fraction of the polyphenolic structural universe has been evaluated. Along these lines, we have developed an in vitro route to the synthesis and subsequent screening of unnatural polyketide analogues with N-acetylcysteamine (SNAc) starter substrates and malonyl-coenzyme A (CoA) and methylmalonyl-CoA as extender substrates. The resulting polyketide analogues possessed a similar structural polyketide backbone (aromatic-2-pyrone) with variable side chains. Screening chalcone synthase (CHS) reaction products against BT-474 cells resulted in identification of several trifluoromethylcinnamoyl-based polyketides that showed strong suppression of the HER2-associated PI3K/AKT signaling pathway, yet did not inhibit the growth of nontransformed MCF-10A breast cells (IC(50)&gt;100 microM). Specifically, 4-trifluoromethylcinnamoyl pyrone (compound 2 e) was highly potent (IC(50)&lt;200 nM) among the test compounds toward proliferation of several breast cancer cell lines. This breadth of activity likely stems from the ability of compound 2 e to inhibit the phosphorylation of HER1, HER2, and HER3. Therefore, these polyketide analogues might prove to be useful drug candidates for potential breast cancer therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kwon</LastName>
                    <ForeName>Seok Joon</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Moon Il</ForeName>
                    <Initials>MI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ku</LastName>
                    <ForeName>Bosung</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coulombel</LastName>
                    <ForeName>Lydie</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Jin-Hwan</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shawky</LastName>
                    <ForeName>Joseph H</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Linhardt</LastName>
                    <ForeName>Robert J</ForeName>
                    <Initials>RJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dordick</LastName>
                    <ForeName>Jonathan S</ForeName>
                    <Initials>JS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>ES012619</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>GM66712</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 GM066712</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 GM066712-01A1</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R41 ES012619</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R41 ES012619-01</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Chembiochem</MedlineTA>
            <NlmUniqueID>100937360</NlmUniqueID>
            <ISSNLinking>1439-4227</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004800">Enzymes, Immobilized</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018942">Macrolides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011753">Pyrones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5UX2SD1KE2</RegistryNumber>
                <NameOfSubstance UI="D003543">Cysteamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.3.-</RegistryNumber>
                <NameOfSubstance UI="D000217">Acyltransferases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.3.1.74</RegistryNumber>
                <NameOfSubstance UI="C020141">flavanone synthetase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.-</RegistryNumber>
                <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D020893">Receptor, ErbB-3</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Oncol. 2003 Sep;23(3):821-9</RefSource>
                <PMID Version="1">12888923</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2003 Oct;3(10):768-80</RefSource>
                <PMID Version="1">14570043</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 Feb 6;279(6):4479-89</RefSource>
                <PMID Version="1">14602723</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2004 Jun 4;304(5676):1497-500</RefSource>
                <PMID Version="1">15118125</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11</RefSource>
                <PMID Version="1">15329413</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 Oct 22;279(43):45162-74</RefSource>
                <PMID Version="1">15265863</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1987 Jan 9;235(4785):177-82</RefSource>
                <PMID Version="1">3798106</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1989 May 12;244(4905):707-12</RefSource>
                <PMID Version="1">2470152</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nat Prod. 1995 Jun;58(6):857-62</RefSource>
                <PMID Version="1">7673929</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol. 1998 Dec;5(12):743-54</RefSource>
                <PMID Version="1">9862800</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1999 Mar 26;274(13):8347-50</RefSource>
                <PMID Version="1">10085060</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Chem. 1999 Oct 7;42(20):4250-6</RefSource>
                <PMID Version="1">10514295</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anticancer Res. 2004 Sep-Oct;24(5A):2783-840</RefSource>
                <PMID Version="1">15517885</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol. 2005 Feb;12(2):163-80</RefSource>
                <PMID Version="1">15734644</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Biotechnol. 2005 Mar;23(3):329-36</RefSource>
                <PMID Version="1">15711537</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2005 Apr 1;11(7):2735-46</RefSource>
                <PMID Version="1">15814656</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2005 May;5(5):341-54</RefSource>
                <PMID Version="1">15864276</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2005 May 15;11(10):3846-53</RefSource>
                <PMID Version="1">15897585</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Med. 2005 Mar;2(3):e73</RefSource>
                <PMID Version="1">15737014</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2005 Aug 10;23(23):5305-13</RefSource>
                <PMID Version="1">15955900</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Oncol. 2005 Dec;16(12):1889-97</RefSource>
                <PMID Version="1">16219625</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Drug Discov. 2005 Dec;4(12):988-1004</RefSource>
                <PMID Version="1">16341064</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2006 Feb 1;66(3):1630-9</RefSource>
                <PMID Version="1">16452222</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 2006 May 14;71(10):1397-421</RefSource>
                <PMID Version="1">16563357</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol. 2006 Jul;13(7):779-86</RefSource>
                <PMID Version="1">16873026</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biofactors. 2006;27(1-4):19-35</RefSource>
                <PMID Version="1">17012761</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>ACS Chem Biol. 2007 Feb 20;2(2):104-8</RefSource>
                <PMID Version="1">17256996</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Org Lett. 2007 May 10;9(10):1895-8</RefSource>
                <PMID Version="1">17439132</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Chem Biol. 2007 Jul;3(7):379-86</RefSource>
                <PMID Version="1">17576425</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>ACS Chem Biol. 2007 Jun 15;2(6):419-25</RefSource>
                <PMID Version="1">17530734</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2007 Oct 1;67(19):9018-23</RefSource>
                <PMID Version="1">17909003</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Phytochemistry. 2007 Nov-Dec;68(22-24):2722-35</RefSource>
                <PMID Version="1">17643453</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Mol Life Sci. 2008 Jun;65(11):1631-52</RefSource>
                <PMID Version="1">18324353</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioorg Med Chem Lett. 2008 Jun 15;18(12):3495-9</RefSource>
                <PMID Version="1">18508264</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cancer Ther. 2008 Jul;7(7):1846-50</RefSource>
                <PMID Version="1">18644997</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Chem. 2008 Aug 14;51(15):4419-29</RefSource>
                <PMID Version="1">18610999</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anal Chem. 2008 Sep 1;80(17):6633-9</RefSource>
                <PMID Version="1">18656951</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Lett. 2008 Oct 8;269(2):226-42</RefSource>
                <PMID Version="1">18492603</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 2009 Jan 21;101(2):107-13</RefSource>
                <PMID Version="1">19141783</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2009 Mar 15;69(6):2191-4</RefSource>
                <PMID Version="1">19276389</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Org Lett. 2009 Sep 3;11(17):3806-9</RefSource>
                <PMID Version="1">19653678</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2009 Sep 1;69(17):6871-8</RefSource>
                <PMID Version="1">19671800</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Pharmacol. 1999 Nov;128(5):999-1010</RefSource>
                <PMID Version="1">10556937</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Chem. 2000 Mar 9;43(5):843-58</RefSource>
                <PMID Version="1">10715152</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2000 Dec 9;279(1):190-5</RefSource>
                <PMID Version="1">11112437</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37</RefSource>
                <PMID Version="1">11252954</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2001 Oct 15;61(20):7408-12</RefSource>
                <PMID Version="1">11606371</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 2001 Dec 11;40(49):14829-38</RefSource>
                <PMID Version="1">11732902</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5319-24</RefSource>
                <PMID Version="1">11959984</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2002 Jul 15;62(14):4132-41</RefSource>
                <PMID Version="1">12124352</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Prod Rep. 2003 Feb;20(1):79-110</RefSource>
                <PMID Version="1">12636085</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Org Lett. 2003 Apr 17;5(8):1277-80</RefSource>
                <PMID Version="1">12688738</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000217">Acyltransferases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003543">Cysteamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004800">Enzymes, Immobilized</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018942">Macrolides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000455">Medicago sativa</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011753">Pyrones</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018719">Receptor, ErbB-2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020893">Receptor, ErbB-3</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS254819</OtherID>
        <OtherID Source="NLM">PMC3094853</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>6</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cbic.200900674</ArticleId>
            <ArticleId IdType="pubmed">20058253</ArticleId>
            <ArticleId IdType="pmc">PMC3094853</ArticleId>
            <ArticleId IdType="mid">NIHMS254819</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11549668</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>09</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>10</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2010</Year>
            <Month>11</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0021-972X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>86</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2001</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of clinical endocrinology and metabolism</Title>
                <ISOAbbreviation>J. Clin. Endocrinol. Metab.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The genetic basis of plasma variation in adiponectin, a global endophenotype for obesity and the metabolic syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4321-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Here we present the first genetic analysis of adiponectin levels, a newly identified adipocyte-derived protein. Recent work has suggested that adiponectin may play a role in mediating the effects of body weight as a risk factor for coronary artery disease. For this analysis we assayed serum levels of adiponectin in 1100 adults of predominantly northern European ancestry distributed across 170 families. Quantitative genetic analysis of adiponectin levels detected an additive genetic heritability of 46%. The maximum LOD score detected in a genome wide scan for adiponectin levels was 4.06 (P = 7.7 x 10(-6)), 35 cM from pter on chromosome 5. The second largest LOD score (LOD = 3.2; P = 6.2 x 10(-5)) was detected on chromosome 14, 29 cM from pter. The detection of a significant linkage with a quantitative trait locus on chromosome 5 provides strong evidence for a replication of a previously reported quantitative trait locus for obesity-related phenotypes. In addition, several secondary signals offer potential evidence of replications for additional previously reported obesity-related quantitative trait loci on chromosomes 2 and 10. Not only do these results identify quantitative trait loci with significant effects on a newly described, and potentially very important, adipocyte-derived protein, they also reveal the emergence of a consistent pattern of linkage results for obesity-related traits across a number of human populations.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Comuzzie</LastName>
                    <ForeName>A G</ForeName>
                    <Initials>AG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio, Texas 78245, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Funahashi</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sonnenberg</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>L J</ForeName>
                    <Initials>LJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacob</LastName>
                    <ForeName>H J</ForeName>
                    <Initials>HJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Black</LastName>
                    <ForeName>A E</ForeName>
                    <Initials>AE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maas</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takahashi</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kihara</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanaka</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsuzawa</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blangero</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kissebah</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DK-54026</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL-34989</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>MH-59490</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RR-00058</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Clin Endocrinol Metab</MedlineTA>
            <NlmUniqueID>0375362</NlmUniqueID>
            <ISSNLinking>0021-972X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D052242">Adiponectin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D052242">Adiponectin</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000273">Adipose Tissue</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002886">Chromosomes, Human, Pair 17</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008040">Genetic Linkage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D036341">Intercellular Signaling Peptides and Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008659">Metabolic Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009765">Obesity</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011506">Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2001</Year>
                <Month>9</Month>
                <Day>11</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2001</Year>
                <Month>9</Month>
                <Day>11</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11549668</ArticleId>
            <ArticleId IdType="doi">10.1210/jcem.86.9.7878</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11080549</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>02</Month>
            <Day>02</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>02</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0166-4328</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>116</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Month>Dec</Month>
                        <Day>5</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Behavioural brain research</Title>
                <ISOAbbreviation>Behav. Brain Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cocaine self-administration behavior can be reduced or potentiated by the addition of specific dopamine concentrations in the nucleus accumbens and amygdala using in vivo microdialysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>177-86</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Potentiation of mesolimbic dopamine levels is generally hypothesized to be reinforcing and contribute to the self-administration of addictive drugs such as cocaine. In the present study, the in vivo microdialysis technique was used to directly manipulate extracellular dopamine concentrations in the nucleus accumbens (NAC) shell and the amygdala (AMY) in rats maintaining stable patterns of cocaine (1.5 mg/kg/infusion) intake under a fixed ratio 1 schedule of reinforcement. In the NAC, a perfusate dopamine concentration of 90 nM was found to reduce cocaine self-administration, whereas a perfusate concentration of 450 nM increased the intake of cocaine. In the AMY, 45 nM perfusate dopamine inhibited cocaine self-administration, whereas 90 nM perfusate dopamine enhanced cocaine intake. The attenuation or potentiation of cocaine intake behavior was maintained throughout the time period (30 or 60 min) of the manipulation of the perfusate dopamine (DA) concentrations in the NAC and AMY. Other perfusate concentrations tested, 180 and 360 nM, in both the nucleus accumbens and amygdala, were without effect on altering the stable pattern of cocaine self-administration behavior. Overall, these experiments show that elevated mesolimbic dopamine concentrations can differentially modulate cocaine self-administration behavior.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hurd</LastName>
                    <ForeName>Y L</ForeName>
                    <Initials>YL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Karolinska Institute, Department Clinical Neuroscience, Psychiatry Section, S-171 76, Stockholm, Sweden. yasmin.hurd@neuro.ks.se</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pontén</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DA08912</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>NETHERLANDS</Country>
            <MedlineTA>Behav Brain Res</MedlineTA>
            <NlmUniqueID>8004872</NlmUniqueID>
            <ISSNLinking>0166-4328</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>VTD58H1Z2X</RegistryNumber>
                <NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000679">Amygdala</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001931">Brain Mapping</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017551">Microdialysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009042">Motivation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009714">Nucleus Accumbens</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012646">Self Administration</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>3</Month>
                <Day>3</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11080549</ArticleId>
            <ArticleId IdType="pii">S0166432800002710</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9882160</PMID>
        <DateCreated>
            <Year>1999</Year>
            <Month>01</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1999</Year>
            <Month>01</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1195-1982</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>5</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1998</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of travel medicine</Title>
                <ISOAbbreviation>J Travel Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A unique case of mefloquine-induced psoriasis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>156</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Potasman</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seligmann</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>CANADA</Country>
            <MedlineTA>J Travel Med</MedlineTA>
            <NlmUniqueID>9434456</NlmUniqueID>
            <ISSNLinking>1195-1982</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>TML814419R</RegistryNumber>
                <NameOfSubstance UI="D015767">Mefloquine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000962">Antimalarials</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001007">Anxiety</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015767">Mefloquine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011565">Psoriasis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014195">Travel</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1999</Year>
                <Month>1</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1999</Year>
                <Month>1</Month>
                <Day>9</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1999</Year>
                <Month>1</Month>
                <Day>9</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9882160</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11080548</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>02</Month>
            <Day>02</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>02</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0166-4328</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>116</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Month>Dec</Month>
                        <Day>5</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Behavioural brain research</Title>
                <ISOAbbreviation>Behav. Brain Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The dopamine D2/D3 antagonist DS121 potentiates the effect of cocaine on locomotion and reduces tolerance in cocaine tolerant rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>169-75</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>To explore the significance of dopamine (DA) autoreceptors in cocaine tolerance and cocaine induced locomotor activity rats were treated with saline and cocaine (40 mg/kg per day via osmotic minipump; normal and cocaine tolerant rats, respectively). Injections of DS121 (0-7 mg/kg, i.p.; S(-)-3-(3-(cyanophenyl)-N-n-propylpiperidine), a DA D2/3 and autoreceptor preferring antagonist, either alone (i.e. DS121 + saline injection) or in combination with cocaine (7.5 mg/kg, i.p.) were also given. DS121 (+ saline) increased locomotor activity in both saline and cocaine pump (CP) treated animals. DS121 also potentiated the effect of cocaine on locomotor activity; this effect was greatest in CP (tolerant) animals. It is concluded that DS121 can increase locomotor activity and that this effect is greatest when the DA tone is high, that is when cocaine is present, suggestive of a presynaptic mechanism. Furthermore, because DS121 potentiation of cocaine induced locomotor activity is greatest in tolerant animals it is concluded that supersensitive DA autoreceptors underlie this effect. These data further support our previous data, which show that DA autoreceptors are sensitized after continuous cocaine (minipump) treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ellinwood</LastName>
                    <ForeName>E H</ForeName>
                    <Initials>EH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, Duke University Medical Center, Box 3870, Durham, NC 27710, USA. ehwood@duke.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>King</LastName>
                    <ForeName>G R</ForeName>
                    <Initials>GR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Davidson</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>T H</ForeName>
                    <Initials>TH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>5U19 DA 109396</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DA-06519</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DA-10327</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>NETHERLANDS</Country>
            <MedlineTA>Behav Brain Res</MedlineTA>
            <NlmUniqueID>8004872</NlmUniqueID>
            <ISSNLinking>0166-4328</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C493595">Drd3 protein, rat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050637">Receptors, Dopamine D3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>150336-90-6</RegistryNumber>
                <NameOfSubstance UI="C094012">3-(3-cyanophenyl)-N-n-propylpiperidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018492">Dopamine Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004361">Drug Tolerance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008124">Locomotion</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009570">Nitriles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010880">Piperidines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017448">Receptors, Dopamine D2</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050637">Receptors, Dopamine D3</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>3</Month>
                <Day>3</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11080548</ArticleId>
            <ArticleId IdType="pii">S0166432800002709</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6091395</PMID>
        <DateCreated>
            <Year>1984</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1984</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0065-1427</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>100</Volume>
                    <PubDate>
                        <Year>1984</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Acta neurologica Scandinavica. Supplementum</Title>
                <ISOAbbreviation>Acta Neurol. Scand., Suppl.c</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A neurological evaluation of purported cases of SMON in Sweden.</ArticleTitle>
            <Pagination>
                <MedlinePgn>165-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Forty Swedish victims of halogenated hydroxyquinoline neurotoxicity were claimed by Dr Hansson in 1981. He had seen only a few of these patients himself. Furthermore, in half the number of patients a neurological examination had been performed only long ago or not at all. A survey of these cases has never been presented. Therefore, extensive and, where possible, complete medical data were obtained for these 40 and one additional patient. A neurological differential diagnostic evaluation was made in each case. It was found that only one had a full-blown SMON syndrome. In all, only half of the patients in this series showed any evidence of a neurotoxic lesion due to clioquinol. The case stories were also presented in detail to the Baumgartner group, with similar diagnostic results. Detailed clinical data and differential diagnoses are presented in the communication.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gilland</LastName>
                    <ForeName>O</ForeName>
                    <Initials>O</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>DENMARK</Country>
            <MedlineTA>Acta Neurol Scand Suppl</MedlineTA>
            <NlmUniqueID>0370337</NlmUniqueID>
            <ISSNLinking>0065-1427</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006912">Hydroxyquinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7BHQ856EJ5</RegistryNumber>
                <NameOfSubstance UI="D007464">Clioquinol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007464">Clioquinol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006912">Hydroxyquinolines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009896">Optic Atrophy</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010523">Peripheral Nervous System Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013118">Spinal Cord Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D013548">Sweden</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1984</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1984</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1984</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6091395</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11501681</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>08</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>09</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0890-8567</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>40</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2001</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of the American Academy of Child and Adolescent Psychiatry</Title>
                <ISOAbbreviation>J Am Acad Child Adolesc Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Valproic acid and risperidone.</ArticleTitle>
            <Pagination>
                <MedlinePgn>866-7</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>van Wattum</LastName>
                    <ForeName>P J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Am Acad Child Adolesc Psychiatry</MedlineTA>
            <NlmUniqueID>8704565</NlmUniqueID>
            <ISSNLinking>0890-8567</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>614OI1Z5WI</RegistryNumber>
                <NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>L6UH7ZF8HC</RegistryNumber>
                <NameOfSubstance UI="D018967">Risperidone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>J Am Acad Child Adolesc Psychiatry. 2002 Jun;41(6):632</RefSource>
                <PMID Version="1">12049437</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>J Am Acad Child Adolesc Psychiatry. 2003 Jan;42(1):1-2</RefSource>
                <PMID Version="1">12500067</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>J Am Acad Child Adolesc Psychiatry. 2003 Jan;42(1):2</RefSource>
                <PMID Version="1">12500068</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000374">Aggression</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002653">Child Behavior Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018967">Risperidone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014635">Valproic Acid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2001</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2001</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11501681</ArticleId>
            <ArticleId IdType="pii">S0890-8567(09)60328-2</ArticleId>
            <ArticleId IdType="doi">10.1097/00004583-200108000-00003</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6091394</PMID>
        <DateCreated>
            <Year>1984</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1984</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0065-1427</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>100</Volume>
                    <PubDate>
                        <Year>1984</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Acta neurologica Scandinavica. Supplementum</Title>
                <ISOAbbreviation>Acta Neurol. Scand., Suppl.c</ISOAbbreviation>
            </Journal>
            <ArticleTitle>SMON as seen from Bombay.</ArticleTitle>
            <Pagination>
                <MedlinePgn>159-64</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Clioquinol is still consumed in India in considerable amounts but no new case reports have appeared since 1977. A review is made for a regional neurotoxicology group of an enquiry that we conducted in Bombay to gather information regarding SMON, spanning the period of 1967 to 1976. Nine patients were diagnosed with a variable degree of confidence as suffering from SMON, two from a retrospective search and seven after a prospective watch for the disease. Myelopathy with predominant more distal dysesthesia was seen more often than the full-blown picture of SMON. The peripheral neuropathy component (N) diagnosed clinically or electrophysiologically was seen only once. Pyramidal tract disturbances and resulting spasticity was as striking as posterior column disorder and sensory ataxia. Subacute myelopathy was seen in six patients, optico-myelopathy in two, and myeloneuropathy only once. It was clear that clioquinol has potential neurotoxicity, but no definitive explanation was forthcoming about the vast difference in the prevalence of SMON as reported from Japan and seen by us in Bombay.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wadia</LastName>
                    <ForeName>N H</ForeName>
                    <Initials>NH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>DENMARK</Country>
            <MedlineTA>Acta Neurol Scand Suppl</MedlineTA>
            <NlmUniqueID>0370337</NlmUniqueID>
            <ISSNLinking>0065-1427</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006912">Hydroxyquinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7BHQ856EJ5</RegistryNumber>
                <NameOfSubstance UI="D007464">Clioquinol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007464">Clioquinol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006912">Hydroxyquinolines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007194">India</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007564">Japan</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009896">Optic Atrophy</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010523">Peripheral Nervous System Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013118">Spinal Cord Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1984</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1984</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1984</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6091394</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18430032</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>04</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>07</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-9568</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>27</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The European journal of neuroscience</Title>
                <ISOAbbreviation>Eur. J. Neurosci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role of GluR1 expression in nucleus accumbens neurons in cocaine sensitization and cocaine-seeking behavior.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2229-40</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1460-9568.2008.06199.x</ELocationID>
            <Abstract>
                <AbstractText>Chronic cocaine use reduces glutamate levels in the nucleus accumbens (NAc), and is associated with experience-dependent changes in (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptor membrane expression in NAc neurons. These changes accompany behavioral sensitization to cocaine and increased susceptibility to cocaine relapse. The functional relationship between neuroplasticity in AMPA receptors and the behavioral manifestation of cocaine addiction remains unclear. Thus, we examined the behavioral effects of up- and downregulating basal AMPA receptor function in the NAc core and shell using viral-mediated gene transfer of wild-type glutamate receptor 1 (wt-GluR1) or a dominant-negative pore-dead GluR1 (pd-GluR1), respectively. Transient increases in wt-GluR1 during or after cocaine treatments diminished the development of cocaine sensitization, while pd-GluR1 expression exacerbated cocaine sensitization. Parallel changes were found in D2, but not D1, receptor-mediated behavioral responses. As a correlate of the sensitization experiments, we overexpressed wt- or pd-GluR1 in the NAc core during cocaine self-administration, and tested the effects on subsequent drug-seeking behavior 3 weeks after overexpression declined. wt-GluR1 overexpression during self-administration had no effect on cocaine intake, but subsequently reduced cocaine seeking in extinction and cocaine-induced reinstatement, whereas pd-GluR1 facilitated cocaine-induced reinstatement. When overexpressed during reinstatement tests, wt-GluR1 directly attenuated cocaine- and D2 agonist-induced reinstatement, while pd-GluR1 enhanced reinstatement. In both experimental procedures, neither wt- nor pd-GluR1 expression affected cue-induced reinstatement. Together, these results suggest that degrading basal AMPA receptor function in NAc neurons is sufficient to facilitate relapse via sensitization in D2 receptor responses, whereas elevating basal AMPA receptor function attenuates these behaviors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bachtell</LastName>
                    <ForeName>Ryan K</ForeName>
                    <Initials>RK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Kwang-Ho</ForeName>
                    <Initials>KH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Simmons</LastName>
                    <ForeName>Diana L</ForeName>
                    <Initials>DL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Falcon</LastName>
                    <ForeName>Edgardo</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Monteggia</LastName>
                    <ForeName>Lisa M</ForeName>
                    <Initials>LM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neve</LastName>
                    <ForeName>Rachael L</ForeName>
                    <Initials>RL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Self</LastName>
                    <ForeName>David W</ForeName>
                    <Initials>DW</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DA 008227</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DA 010460</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DA 018481</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DA 18743</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01 DA008227</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DA010460</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DA018743</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>04</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Eur J Neurosci</MedlineTA>
            <NlmUniqueID>8918110</NlmUniqueID>
            <ISSNLinking>0953-816X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C097222">glutamate receptor ionotropic, AMPA 1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016739">Behavior, Addictive</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001522">Behavior, Animal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005822">Genetic Vectors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009473">Neuronal Plasticity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009714">Nucleus Accumbens</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018091">Receptors, AMPA</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017447">Receptors, Dopamine D1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017448">Receptors, Dopamine D2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>4</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>4</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">EJN6199</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1460-9568.2008.06199.x</ArticleId>
            <ArticleId IdType="pubmed">18430032</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17919350</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>10</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1526-8209</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical breast cancer</Title>
                <ISOAbbreviation>Clin. Breast Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>697-704</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">In order to evaluate the feasibility of dose-dense docetaxel followed by dose-dense AC (doxorubicin/cyclophosphamide) as adjuvant chemotherapy for operable breast cancer, we conducted a phase II study.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">In cohort 1, 28 patients received docetaxel 100 mg/m2 followed by doxorubicin 60 mg/m2 with cyclophosphamide 600 mg/m2, each every 2 weeks for 4 weeks (total of 8 cycles). Enrollment was discontinued because of stopping criteria based on significant toxicity (grade 4 hematologic toxicity or grade &gt;or= 3 nonhematologic toxicity). In cohort 2, the docetaxel dose was reduced to 75 mg/m2; enrollment was discontinued after 18 patients.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Significant toxicity occurred in 79% and 72% of patients in cohorts 1 and 2, respectively, resulting in treatment delays in 50% and 17% of patients, respectively. The most common grade 4 hematologic toxicity was neutropenia, which occurred in 7% and 42% of cohort 1 patients during docetaxel and AC, respectively, and in none and 19% of cohort 2 patients, respectively. The most common grade &gt;or= 3 nonhematologic toxicity was palmar-plantar erythrodysesthesia, which occurred in 25% and none of cohort 1 patients during docetaxel and AC, respectively. With docetaxel 75 mg/m2 and patient education encouraging routine use of topical strategies, grade 3 palmar-plantar erythrodysesthesia occurred in only 11% of cohort 2 patients. Grade 2 nail changes were also debilitating and occurred in 33% of cohort 1 patients during AC.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These phase II findings suggest that dose-dense docetaxel 100 mg/m2 followed by AC is not feasible and, until more studies are conducted, should be restricted to clinical studies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lambert-Falls</LastName>
                    <ForeName>Rosemary</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>South Carolina Oncology Associates, Columbia, SC 29210, USA. rlambertfalls@sconcology.net</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Modugno</LastName>
                    <ForeName>Susan</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Breast Cancer</MedlineTA>
            <NlmUniqueID>100898731</NlmUniqueID>
            <ISSNLinking>1526-8209</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D043823">Taxoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>15H5577CQD</RegistryNumber>
                <NameOfSubstance UI="C067311">docetaxel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8N3DW7272P</RegistryNumber>
                <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017024">Chemotherapy, Adjuvant</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003520">Cyclophosphamide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003875">Drug Eruptions</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D064420">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005240">Feasibility Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005533">Foot Dermatoses</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006229">Hand Dermatoses</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009503">Neutropenia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010292">Paresthesia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D043823">Taxoids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>6</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17919350</ArticleId>
            <ArticleId IdType="pii">S1526-8209(11)70764-9</ArticleId>
            <ArticleId IdType="doi">10.3816/CBC.2007.n.029</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17919354</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>10</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1526-8209</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical breast cancer</Title>
                <ISOAbbreviation>Clin. Breast Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>716-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Porphyria cutanea tarda (PCT) is sometimes precipitated or aggravated by increased exposure to estrogen, estrogen-like compounds, or tamoxifen. We report the case of a 37-year-old white woman who developed sporadic PCT after she took oral contraceptives for 10 years. She was heterozygous for the common H63D mutation of the hemochromatosis-associated HFE gene. The PCT responded partially to the cessation of oral contraceptives and to phlebotomy therapy to maintain low iron stores, but only remitted after she received anastrozole therapy for management of adenocarcinoma of the breast at age 59 years. The pertinence of HFE mutations, anastrozole and tamoxifen treatment, and chemotherapy to the development and management of PCT in women with breast cancer is discussed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bertoli</LastName>
                    <ForeName>Luigi F</ForeName>
                    <Initials>LF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brookwood Medical Center, Birmingham, AL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barton</LastName>
                    <ForeName>James C</ForeName>
                    <Initials>JC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Breast Cancer</MedlineTA>
            <NlmUniqueID>100898731</NlmUniqueID>
            <ISSNLinking>1526-8209</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003276">Contraceptives, Oral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C103673">HFE protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2Z07MYW1AZ</RegistryNumber>
                <NameOfSubstance UI="C090450">anastrozole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-73-2</RegistryNumber>
                <NameOfSubstance UI="D005293">Ferritins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018931">Antineoplastic Agents, Hormonal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003276">Contraceptives, Oral</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005293">Ferritins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015395">Histocompatibility Antigens Class I</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008565">Membrane Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009570">Nitriles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018962">Phlebotomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017119">Porphyria Cutanea Tarda</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014230">Triazoles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>28</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>6</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17919354</ArticleId>
            <ArticleId IdType="pii">S1526-8209(11)70768-6</ArticleId>
            <ArticleId IdType="doi">10.3816/CBC.2007.n.033</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9093492</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>04</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>04</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0007-1250</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>170</Volume>
                    <PubDate>
                        <Year>1997</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The British journal of psychiatry : the journal of mental science</Title>
                <ISOAbbreviation>Br J Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Paroxetine-induced chorea.</ArticleTitle>
            <Pagination>
                <MedlinePgn>193-4</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fox</LastName>
                    <ForeName>G C</ForeName>
                    <Initials>GC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ebeid</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vincenti</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Br J Psychiatry</MedlineTA>
            <NlmUniqueID>0342367</NlmUniqueID>
            <ISSNLinking>0007-1250</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>41VRH5220H</RegistryNumber>
                <NameOfSubstance UI="D017374">Paroxetine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018687">Antidepressive Agents, Second-Generation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002819">Chorea</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017374">Paroxetine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1997</Year>
                <Month>2</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1997</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1997</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9093492</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22700541</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>09</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0929</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>129</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicological sciences : an official journal of the Society of Toxicology</Title>
                <ISOAbbreviation>Toxicol. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Late-onset increases in oxidative stress and other tumorigenic activities and tumors with a Ha-ras mutation in the liver of adult male C3H mice gestationally exposed to arsenic.</ArticleTitle>
            <Pagination>
                <MedlinePgn>293-304</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/toxsci/kfs203</ELocationID>
            <Abstract>
                <AbstractText>Tumorigenesis is a complex process involving genetic, epigenetic, and metabolic alterations. Gestational arsenic exposure has been shown to increase hepatic tumors in adult male offspring of C3H mice, which spontaneously develop hepatic tumors often harboring activating Ha-ras mutation. We explored tumor-promoting changes by gestational arsenic exposure with a focus on Ha-ras mutation and gene expression changes. The results of this study demonstrated that gestational arsenic exposure particularly increased hepatic tumors with a C61A Ha-ras mutation. Real-time PCR analyses on the adult normal livers showed that two genes (Creld2, Slc25a30), whose expression are induced by endoplasmic reticulum stress and cellular oxidative stress, respectively, were significantly upregulated and two genes (Fabp4, Ell3), whose products are involved in lipid efflux and apoptosis, respectively, were significantly downregulated more than twofold by gestational arsenic exposure compared with control mice. The expression changes in the four genes were shown to be late-onset events and to some extent to be associated with corresponding histone modifications, and not with DNA methylation changes. The gene expression changes suggested alterations in lipid metabolism and associated oxidative stress augmentation. Consistently, expression of an oxidative-stress-inducible gene heme oxygenase-1 (HO-1) was upregulated in the livers of the arsenic group. We also found increased expression of retrotransposon L1 mRNA in the tumor-bearing livers of the arsenic group in comparison with control mice. These results suggested that gestational arsenic exposure induces tumor-augmenting changes, including oxidative stress and L1 activation, in a late-onset manner, which would particularly promote tumorigenic expansion of cells with a C61A Ha-ras mutation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nohara</LastName>
                    <ForeName>Keiko</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Environmental Health Sciences, National Institute for Environmental Studies, Tsukuba 305-8506, Japan. keikon@nies.go.jp</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tateishi</LastName>
                    <ForeName>Yukiyo</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suzuki</LastName>
                    <ForeName>Takehiro</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okamura</LastName>
                    <ForeName>Kazuyuki</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murai</LastName>
                    <ForeName>Hikari</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takumi</LastName>
                    <ForeName>Shota</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maekawa</LastName>
                    <ForeName>Fumihiko</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishimura</LastName>
                    <ForeName>Noriko</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kobori</LastName>
                    <ForeName>Masuko</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ito</LastName>
                    <ForeName>Takaaki</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Toxicol Sci</MedlineTA>
            <NlmUniqueID>9805461</NlmUniqueID>
            <ISSNLinking>1096-0929</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002273">Carcinogens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>N712M78A8G</RegistryNumber>
                <NameOfSubstance UI="D001151">Arsenic</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001151">Arsenic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002273">Carcinogens</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D047369">Chromatin Immunoprecipitation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011905">Genes, ras</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008114">Liver Neoplasms, Experimental</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D018811">Maternal Exposure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008809">Mice, Inbred C3H</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D018384">Oxidative Stress</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>6</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>6</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>6</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">kfs203</ArticleId>
            <ArticleId IdType="doi">10.1093/toxsci/kfs203</ArticleId>
            <ArticleId IdType="pubmed">22700541</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1196872</PMID>
        <DateCreated>
            <Year>1976</Year>
            <Month>02</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1976</Year>
            <Month>02</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0301-1518</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>4</Volume>
                    <Issue>35</Issue>
                    <PubDate>
                        <Year>1975</Year>
                        <Month>Oct</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>La Nouvelle presse médicale</Title>
                <ISOAbbreviation>Nouv Presse Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[The deterioration of patients with parkinsonism treated with L-dopa].</ArticleTitle>
            <Pagination>
                <MedlinePgn>2503-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A progressive deterioration in clinical state was noted in more than half of a group of 87 patients with parkinsonism treated with dopa for 4 to 6 years. The pattern of this deterioration is often quite particular: frequency of troubles with walking, falls, predominance of akinesia in certain motor functions, inconstant recurrence of tremor or rigidity. Some intellectual deterioration is sometimes seen, more common in those patients who had suffered episodes of mental confusion. 11 patients died. It may, however, be hoped that the average life expectancy will increase.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Guillard</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>fre</Language>
            <PublicationTypeList>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Le &quot;déclin&quot; des parkinsoniens traités par la L-dopa</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>FRANCE</Country>
            <MedlineTA>Nouv Presse Med</MedlineTA>
            <NlmUniqueID>0312552</NlmUniqueID>
            <ISSNLinking>0301-1518</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>46627O600J</RegistryNumber>
                <NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009129">Muscle Tonus</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004856">Postural Balance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014202">Tremor</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1975</Year>
                <Month>10</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1975</Year>
                <Month>10</Month>
                <Day>18</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1975</Year>
                <Month>10</Month>
                <Day>18</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1196872</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15645224</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>04</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>10</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0033-3158</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>179</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Psychopharmacology</Title>
                <ISOAbbreviation>Psychopharmacology (Berl.)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat.</ArticleTitle>
            <Pagination>
                <MedlinePgn>336-48</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Phencyclidine (PCP), a glutamate/N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to induce a range of symptoms similar to those of patients with schizophrenia, while D-amphetamine induces predominantly positive symptoms. Previous studies in our laboratory have shown that PCP can selectively impair the performance of an operant reversal-learning task in the rat. Furthermore, we found that the novel antipsychotic ziprasidone, but not the classical antipsychotic haloperidol, could prevent the PCP-induced deficit.</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of the present study was to validate the model further using the atypical antipsychotic clozapine and then to investigate the effects of lamotrigine, a broad-spectrum anticonvulsant that is known to reduce glutamate release in vitro and is able to prevent ketamine-induced psychotic symptoms in healthy human volunteers. A further aim was to compare effects of PCP and D-amphetamine in the test and investigate the effects of the typical antipsychotic haloperidol against the latter.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Female hooded-Lister rats were food deprived and trained to respond for food in a reversal-learning paradigm.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">PCP at 1.5 mg/kg and 2.0 mg/kg and D-amphetamine at 0.5 mg/kg significantly and selectively impaired performance in the reversal phase of the task. The cognitive deficit induced by 1.5 mg/kg PCP was attenuated by prior administration of lamotrigine (20 mg/kg and 30 mg/kg) or clozapine (5 mg/kg), but not haloperidol (0.05 mg/kg). In direct contrast, haloperidol (0.05 mg/kg), but not lamotrigine (25 mg/kg) or clozapine (5 mg/kg), prevented a similar cognitive impairment produced by D-amphetamine (0.5 mg/kg).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings provide further data to support the use of PCP-induced disruption of reversal learning in rodents to investigate novel antipsychotic drugs. The results also provide evidence for different mechanisms of PCP and D-amphetamine-induced disruption of performance in the test, and their different sensitivities to typical and atypical antipsychotic drugs.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Idris</LastName>
                    <ForeName>N F</ForeName>
                    <Initials>NF</Initials>
                    <AffiliationInfo>
                        <Affiliation>The School of Pharmacy, The University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Repeto</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neill</LastName>
                    <ForeName>J C</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Large</LastName>
                    <ForeName>C H</ForeName>
                    <Initials>CH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2005</Year>
                <Month>01</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Psychopharmacology (Berl)</MedlineTA>
            <NlmUniqueID>7608025</NlmUniqueID>
            <ISSNLinking>0033-3158</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006213">Hallucinogens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014227">Triazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J1DOI7UV76</RegistryNumber>
                <NameOfSubstance UI="D010622">Phencyclidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J60AR2IKIC</RegistryNumber>
                <NameOfSubstance UI="D003024">Clozapine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J6292F8L3D</RegistryNumber>
                <NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>TZ47U051FI</RegistryNumber>
                <NameOfSubstance UI="D003913">Dextroamphetamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U3H27498KS</RegistryNumber>
                <NameOfSubstance UI="C047781">lamotrigine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018692">Antimanic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000697">Central Nervous System Stimulants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003024">Clozapine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003216">Conditioning, Operant</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003913">Dextroamphetamine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006213">Hallucinogens</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006220">Haloperidol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007859">Learning Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010622">Phencyclidine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012193">Reversal Learning</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014227">Triazines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2003</Year>
                <Month>2</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2004</Year>
                <Month>9</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2005</Year>
                <Month>1</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>1</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>10</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>1</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-004-2058-5</ArticleId>
            <ArticleId IdType="pubmed">15645224</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24952746</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>07</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2015</Year>
            <Month>01</Month>
            <Day>12</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>46</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The genomic landscape of nasopharyngeal carcinoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>866-71</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.3006</ELocationID>
            <Abstract>
                <AbstractText>Nasopharyngeal carcinoma (NPC) has extremely skewed ethnic and geographic distributions, is poorly understood at the genetic level and is in need of effective therapeutic approaches. Here we determined the mutational landscape of 128 cases with NPC using whole-exome and targeted deep sequencing, as well as SNP array analysis. These approaches revealed a distinct mutational signature and nine significantly mutated genes, many of which have not been implicated previously in NPC. Notably, integrated analysis showed enrichment of genetic lesions affecting several important cellular processes and pathways, including chromatin modification, ERBB-PI3K signaling and autophagy machinery. Further functional studies suggested the biological relevance of these lesions to the NPC malignant phenotype. In addition, we uncovered a number of new druggable candidates because of their genomic alterations. Together our study provides a molecular basis for a comprehensive understanding of, and exploring new therapies for, NPC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>De-Chen</ForeName>
                    <Initials>DC</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2] Division of Hematology/Oncology, Cedars-Sinai Medical Center, University of California, Los Angeles School of Medicine, Los Angeles, California, USA. [3].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meng</LastName>
                    <ForeName>Xuan</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2] Department of Medicine, School of Medicine, National University of Singapore, Singapore. [3].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hazawa</LastName>
                    <ForeName>Masaharu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nagata</LastName>
                    <ForeName>Yasunobu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. [2] Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Varela</LastName>
                    <ForeName>Ana Maria</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Liang</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sato</LastName>
                    <ForeName>Yusuke</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. [2] Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Li-Zhen</ForeName>
                    <Initials>LZ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ding</LastName>
                    <ForeName>Ling-Wen</ForeName>
                    <Initials>LW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sharma</LastName>
                    <ForeName>Arjun</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Science Institute of Singapore, National University of Singapore, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goh</LastName>
                    <ForeName>Boon Cher</ForeName>
                    <Initials>BC</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2] Department of Haematology-Oncology, National University Cancer Institute, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Soo Chin</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2] Department of Haematology-Oncology, National University Cancer Institute, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Petersson</LastName>
                    <ForeName>Bengt Fredrik</ForeName>
                    <Initials>BF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, National University Health System, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Feng Gang</ForeName>
                    <Initials>FG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Otolaryngology, National University Hospital Singapore, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Macary</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, National University of Singapore, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oo</LastName>
                    <ForeName>Min Zin</ForeName>
                    <Initials>MZ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, National University of Singapore, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ha</LastName>
                    <ForeName>Chan Soh</ForeName>
                    <Initials>CS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbiology, National University of Singapore, Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Henry</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ogawa</LastName>
                    <ForeName>Seishi</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. [2] Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. [3].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loh</LastName>
                    <ForeName>Kwok Seng</ForeName>
                    <Initials>KS</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Otolaryngology, National University Hospital Singapore, Singapore. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koeffler</LastName>
                    <ForeName>H Phillip</ForeName>
                    <Initials>HP</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [2] Division of Hematology/Oncology, Cedars-Sinai Medical Center, University of California, Los Angeles School of Medicine, Los Angeles, California, USA. [3] National University Cancer Institute, National University Hospital Singapore, Singapore. [4].</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>GEO</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>GSE57100</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
                <DataBank>
                    <DataBankName>SRA</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>SRP035573</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01CA026038-35</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>06</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 2.7.1.-</RegistryNumber>
                <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <SupplMeshList>
            <SupplMeshName Type="Disease" UI="C538339">Nasopharyngeal carcinoma</SupplMeshName>
        </SupplMeshList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Genet. 2014 Aug;46(8):809-10</RefSource>
                <PMID Version="1">25215372</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Genet. 2014 Aug;46(8):809-10</RefSource>
                <PMID Version="1">25070800</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001343">Autophagy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059472">Exome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D023281">Genomics</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D064593">Heterografts</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016688">Mice, Inbred NOD</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016513">Mice, SCID</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009303">Nasopharyngeal Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019869">Phosphatidylinositol 3-Kinases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011958">Receptor, Epidermal Growth Factor</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>1</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.3006</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.3006</ArticleId>
            <ArticleId IdType="pubmed">24952746</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15175183</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>06</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>08</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0091-6765</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>112</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Environmental health perspectives</Title>
                <ISOAbbreviation>Environ. Health Perspect.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The effect of disinfection by-products and mutagenic activity on birth weight and gestational duration.</ArticleTitle>
            <Pagination>
                <MedlinePgn>920-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Epidemiologic studies of disinfection by-products have traditionally focused on total trihalomethane (TTHM) concentration as a surrogate for maternal exposure during pregnancy. We used birth certificate data on 196,000 infants to examine the effect of third-trimester exposures on various indices of fetal development. We examined the effect of town-average concentrations of TTHM and additional exposure metrics in relation to mean birth weight, mean gestational age, small for gestational age (SGA) infancy, and preterm delivery. Trihalomethane data (TTHM, chloroform, and bromodichloromethane) from 1995-1998 were available for 109 towns in Massachusetts. Data from 1997-1998 on haloacetic acid (total haloacetic acids, dichloroacetic acid, and trichloroacetic acid), 3-chloro-4-(dichloromethyl)-5- hydroxy-2(5H)-furanone (MX), and mutagenicity were available for a limited number of towns. We observed reductions in mean birth weight (12-18 g) for maternal trihalomethane exposures &gt; the 90th percentile compared with those &lt; the 50th percentile. Birth weight reductions were detected for chloroform exposures &gt; 20 microg/L and TTHM exposures &gt; 40 microg/L. Elevated trihalomethanes were associated with increases in gestational duration and a reduced risk of preterm delivery. We found evidence of an exposure-response effect of trihalomethanes on risk of SGA, with odds ratios (ORs) ranging from 1.09 to 1.23 for bromodichloromethane exposures &gt; 5 microg/L. Elevated mutagenic activity was associated with SGA [OR = 1.25; 95% confidence interval (CI), 1.04 to 1.51] and mean birth weight (-27 g; 95% CI, -54 to -1). Although smaller in magnitude, our findings are consistent with previous studies reporting associations between trihalomethanes and SGA. These data also suggest a relationship between fetal development indices and mutagenic activity independent of exposure to trihalomethanes, haloacetic acids, and MX.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wright</LastName>
                    <ForeName>J Michael</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Office of Research and Development, National Center for Environmental Assessment, U.S. Environmental Protection Agency, 26 W. Martin Luther King Drive (MS-90), Cincinnati, OH 45268, USA. wright.michael@epa.gov</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schwartz</LastName>
                    <ForeName>Joel</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dockery</LastName>
                    <ForeName>Douglas W</ForeName>
                    <Initials>DW</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>ES 00002</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Environ Health Perspect</MedlineTA>
            <NlmUniqueID>0330411</NlmUniqueID>
            <ISSNLinking>0091-6765</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000085">Acetates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005663">Furans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009153">Mutagens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D022882">Trihalomethanes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>77439-76-0</RegistryNumber>
                <NameOfSubstance UI="C054121">3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 1996 Oct;104(10):1056-61</RefSource>
                <PMID Version="1">8930546</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Epidemiology. 1992 Sep;3(5):407-13</RefSource>
                <PMID Version="1">1391132</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Epidemiology. 1998 Mar;9(2):134-40</RefSource>
                <PMID Version="1">9504280</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Toxicol Environ Health A. 1998 Apr 24;53(8):607-14</RefSource>
                <PMID Version="1">9572159</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Epidemiology. 1998 Sep;9(5):484-9</RefSource>
                <PMID Version="1">9730025</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Horm Res. 1998;49 Suppl 2:1-6</RefSource>
                <PMID Version="1">9730664</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 1999 Jan;107(1):17-25</RefSource>
                <PMID Version="1">9872713</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Public Health. 1999 Feb;89(2):213-8</RefSource>
                <PMID Version="1">9949752</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Epidemiology. 1999 May;10(3):233-7</RefSource>
                <PMID Version="1">10230830</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Epidemiology. 1999 Jul;10(4):383-90</RefSource>
                <PMID Version="1">10401872</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2000 Feb;108(2):173-6</RefSource>
                <PMID Version="1">10656859</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Occup Environ Med. 2000 Feb;57(2):73-85</RefSource>
                <PMID Version="1">10711274</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Epidemiol. 2000 Mar 15;151(6):602-13</RefSource>
                <PMID Version="1">10733042</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2000 Sep;108(9):883-6</RefSource>
                <PMID Version="1">11017894</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Occup Environ Med. 2001 Jul;58(7):447-52</RefSource>
                <PMID Version="1">11404449</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2001 Jun;109 Suppl 3:351-6</RefSource>
                <PMID Version="1">11427384</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Regul Toxicol Pharmacol. 2001 Oct;34(2):103-24</RefSource>
                <PMID Version="1">11603954</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2002 Feb;110(2):157-64</RefSource>
                <PMID Version="1">11836144</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Paediatr Perinat Epidemiol. 2002 Jan;16(1):8-15</RefSource>
                <PMID Version="1">11856451</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2002 Oct 1;184(1):19-26</RefSource>
                <PMID Version="1">12392965</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Expo Anal Environ Epidemiol. 2003 Jan;13(1):17-23</RefSource>
                <PMID Version="1">12595880</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Occup Environ Med. 2003 Mar;60(3):173-80</RefSource>
                <PMID Version="1">12598663</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1974 Jun;28(3):442-51</RefSource>
                <PMID Version="1">4851839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1979 Sep 30;50(3):515-22</RefSource>
                <PMID Version="1">516065</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Public Health. 1980 Sep;70(9):964-73</RefSource>
                <PMID Version="1">7406096</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Environ Health. 1993 Mar-Apr;48(2):114-9</RefSource>
                <PMID Version="1">8476302</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Ist Super Sanita. 1993;29(2):279-91</RefSource>
                <PMID Version="1">8279719</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 1995 Mar 1;273(9):709-11</RefSource>
                <PMID Version="1">7853628</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Epidemiol. 1995 May 1;141(9):850-62</RefSource>
                <PMID Version="1">7717362</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 1995 Jun;103(6):592-6</RefSource>
                <PMID Version="1">7556013</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 1996 Jan;104(1):48-51</RefSource>
                <PMID Version="1">8834861</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Public Health Rep. 1996 Sep-Oct;111(5):408-18; discussion 419</RefSource>
                <PMID Version="1">8837629</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mutat Res. 1983 May;113(3-4):173-215</RefSource>
                <PMID Version="1">6341825</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Environ Sci Health B. 1983;18(3):333-49</RefSource>
                <PMID Version="1">6875216</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1985 Jan 10;312(2):82-90</RefSource>
                <PMID Version="1">3880598</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicology. 1987 Oct 12;46(1):83-93</RefSource>
                <PMID Version="1">3660423</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Mol Mutagen. 1987;10(2):211-26</RefSource>
                <PMID Version="1">2446868</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Epidemiol. 1988;41(1):15-20</RefSource>
                <PMID Version="1">3335868</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Teratology. 1988 Aug;38(2):113-20</RefSource>
                <PMID Version="1">3175945</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fundam Appl Toxicol. 1989 May;12(4):765-72</RefSource>
                <PMID Version="1">2744278</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Teratology. 1989 Nov;40(5):445-51</RefSource>
                <PMID Version="1">2623633</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Mol Mutagen. 1991;17(1):32-9</RefSource>
                <PMID Version="1">1991457</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1974 Sep;29(3):348-57</RefSource>
                <PMID Version="1">4283698</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Environ Health. 1992 May-Jun;47(3):236-8</RefSource>
                <PMID Version="1">1596108</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Teratology. 1992 Sep;46(3):217-23</RefSource>
                <PMID Version="1">1523579</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Teratology. 1992 Sep;46(3):225-35</RefSource>
                <PMID Version="1">1523580</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 1997 May;105(5):514-20</RefSource>
                <PMID Version="1">9222137</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000085">Acetates</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D001719">Birth Certificates</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001724">Birth Weight</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004249">DNA Damage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004203">Disinfection</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016021">Epidemiologic Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005663">Furans</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005865">Gestational Age</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D007236">Infant, Small for Gestational Age</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009152">Mutagenicity Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009153">Mutagens</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007752">Obstetric Labor, Premature</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016017">Odds Ratio</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011256">Pregnancy Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011263">Pregnancy Trimester, Third</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D022882">Trihalomethanes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018508">Water Purification</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1242023</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>6</Month>
                <Day>4</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>6</Month>
                <Day>4</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15175183</ArticleId>
            <ArticleId IdType="pmc">PMC1242023</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2074636</PMID>
        <DateCreated>
            <Year>1991</Year>
            <Month>04</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1991</Year>
            <Month>04</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2006</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0022-9032</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>33</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>1990</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Kardiologia polska</Title>
                <ISOAbbreviation>Kardiol Pol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Acute myocardial infarction as a consequence of anaphylactic reaction after administration of urovision].</ArticleTitle>
            <Pagination>
                <MedlinePgn>26-31</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The case of 52-year old patient was presented who developed urticaria and strong anginal pain after intravenous administration of uropoline. On the basis of typical clinical picture, electrocardiographical and biochemical changes acute myocardial infarction was recognised. It is thought to have developed as the consequence of anaphylactic reaction following intravenous administration of x-rays contrast substance.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kwaśniewski</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Katedry i Kliniki Chorób Wewnetrznych i Alergologii AM we Wrocławiu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krasnowska</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>pol</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Zawał mieśnia sercowego jako nastepstwo odczynu anafilaktoidalnego po podaniu uropoliny.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>POLAND</Country>
            <MedlineTA>Kardiol Pol</MedlineTA>
            <NlmUniqueID>0376352</NlmUniqueID>
            <ISSNLinking>0022-9032</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>117-96-4</RegistryNumber>
                <NameOfSubstance UI="D003973">Diatrizoate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>131-49-7</RegistryNumber>
                <NameOfSubstance UI="D003974">Diatrizoate Meglumine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8064-12-8</RegistryNumber>
                <NameOfSubstance UI="C027278">urovision</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000707">Anaphylaxis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003287">Contrast Media</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003973">Diatrizoate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003974">Diatrizoate Meglumine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004342">Drug Hypersensitivity</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009203">Myocardial Infarction</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2074636</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10751776</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>05</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>05</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1522-1946</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>49</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title>
                <ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Percutaneous transluminal coronary angioplasty and stenting for cocaine-induced acute myocardial infarction: a case report and review.</ArticleTitle>
            <Pagination>
                <MedlinePgn>447-51</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Cocaine-induced myocardial infarction has been well reported. Likewise, there are numerous reports of patients with cocaine-induced myocardial infarction being treated conservatively with nitroglycerin, verapamil, and thrombolytics. However, based on a Medline search from 1977 to 1998 (with the keywords cocaine and angioplasty), there have been no reports in English of cocaine-induced myocardial infarction being treated with catheter-based intervention. We report such a case, as well as review what is known about the pathophysiology of cocaine-induced coronary arteriopathy and myocardial infarction.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shah</LastName>
                    <ForeName>D M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, William Beaumont Hospital, Royal Oak, Michigan, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dy</LastName>
                    <ForeName>T C</ForeName>
                    <Initials>TC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Szto</LastName>
                    <ForeName>G Y</ForeName>
                    <Initials>GY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Linnemeier</LastName>
                    <ForeName>T J</ForeName>
                    <Initials>TJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Catheter Cardiovasc Interv</MedlineTA>
            <NlmUniqueID>100884139</NlmUniqueID>
            <ISSNLinking>1522-1946</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D015906">Angioplasty, Balloon, Coronary</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017023">Coronary Angiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009203">Myocardial Infarction</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000530">radiography</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D015607">Stents</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014662">Vasoconstrictor Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>33</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2001</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>11</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2001</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10751776</ArticleId>
            <ArticleId IdType="pii">10.1002/(SICI)1522-726X(200004)49:4&lt;447::AID-CCD22&gt;3.0.CO;2-J</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">5351331</PMID>
        <DateCreated>
            <Year>1970</Year>
            <Month>01</Month>
            <Day>02</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1970</Year>
            <Month>01</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0012-0472</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>94</Volume>
                    <Issue>48</Issue>
                    <PubDate>
                        <Year>1969</Year>
                        <Month>Nov</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Deutsche medizinische Wochenschrift (1946)</Title>
                <ISOAbbreviation>Dtsch. Med. Wochenschr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Norethisterone enanthate. Studies during the use of a long-acting parenteral contraceptive].</ArticleTitle>
            <Pagination>
                <MedlinePgn>2473-7</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gilfrich</LastName>
                    <ForeName>H J</ForeName>
                    <Initials>HJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nieschlag</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dudeck</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Overzier</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>ger</Language>
            <PublicationTypeList>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Norethisteronönanthat. Untersuchungen während der Anwendung eines langwirkenden parenteralen Kontrazeptivum.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>GERMANY, WEST</Country>
            <MedlineTA>Dtsch Med Wochenschr</MedlineTA>
            <NlmUniqueID>0006723</NlmUniqueID>
            <ISSNLinking>0012-0472</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003276">Contraceptives, Oral</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.6.1.1</RegistryNumber>
                <NameOfSubstance UI="D001219">Aspartate Aminotransferases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.6.1.2</RegistryNumber>
                <NameOfSubstance UI="D000410">Alanine Transaminase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>T18F433X4S</RegistryNumber>
                <NameOfSubstance UI="D009640">Norethindrone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CitationSubset>J</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000311">Adrenal Glands</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000410">Alanine Transaminase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001219">Aspartate Aminotransferases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001798">Blood Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001809">Blood Viscosity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001831">Body Temperature</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003276">Contraceptives, Oral</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003692">Delayed-Action Preparations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005951">Glucose Tolerance Test</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006470">Hemorrhage</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007273">Injections, Intramuscular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009640">Norethindrone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013927">Thrombosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014280">Triglycerides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="PIP">690070</OtherID>
        <OtherID Source="POP">00018179</OtherID>
        <OtherAbstract Type="PIP" Language="eng">
            <AbstractText>The effect of norethisterone enanthate on clinical and biochemical parameters was studied in 9 normal women aged 21-29 years. Blood samples were taken before and 2, 6, 10, and 14 weeks after injection. Significant changes in serum proteins were observed, as was a significant increase in blood coagulability. Serum triglycerides were significantly lower. Thrombosis and effects on adrenal cortex function and on glucose tolerance were not observed. Side effects included breakthrough bleeding, nausea, headache, fatigue, nervousness, breast tension, and backache.</AbstractText>
        </OtherAbstract>
        <KeywordList Owner="PIP">
            <Keyword MajorTopicYN="N">Biology</Keyword>
            <Keyword MajorTopicYN="Y">Clinical Research</Keyword>
            <Keyword MajorTopicYN="N">Contraception</Keyword>
            <Keyword MajorTopicYN="N">Contraceptive Agents, Female--side effects</Keyword>
            <Keyword MajorTopicYN="N">Contraceptive Agents, Progestin--side effects</Keyword>
            <Keyword MajorTopicYN="N">Contraceptive Agents--side effects</Keyword>
            <Keyword MajorTopicYN="N">Family Planning</Keyword>
            <Keyword MajorTopicYN="Y">Hematological Effects--etiology</Keyword>
            <Keyword MajorTopicYN="N">Hemic System</Keyword>
            <Keyword MajorTopicYN="Y">Norethindrone Enanthate--side effects</Keyword>
            <Keyword MajorTopicYN="N">Norethindrone--side effects</Keyword>
            <Keyword MajorTopicYN="N">Physiology</Keyword>
            <Keyword MajorTopicYN="N">Research Methodology</Keyword>
            <Keyword MajorTopicYN="Y">Serum Protein Effects--etiology</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1969</Year>
                <Month>11</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1969</Year>
                <Month>11</Month>
                <Day>28</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1969</Year>
                <Month>11</Month>
                <Day>28</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">5351331</ArticleId>
            <ArticleId IdType="doi">10.1055/s-0028-1110466</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24952744</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>07</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2015</Year>
            <Month>01</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>02</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>46</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>837-43</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.3013</ELocationID>
            <Abstract>
                <AbstractText>Cancer genome sequencing studies have identified numerous driver genes, but the relative timing of mutations in carcinogenesis remains unclear. The gradual progression from premalignant Barrett's esophagus to esophageal adenocarcinoma (EAC) provides an ideal model to study the ordering of somatic mutations. We identified recurrently mutated genes and assessed clonal structure using whole-genome sequencing and amplicon resequencing of 112 EACs. We next screened a cohort of 109 biopsies from 2 key transition points in the development of malignancy: benign metaplastic never-dysplastic Barrett's esophagus (NDBE; n=66) and high-grade dysplasia (HGD; n=43). Unexpectedly, the majority of recurrently mutated genes in EAC were also mutated in NDBE. Only TP53 and SMAD4 mutations occurred in a stage-specific manner, confined to HGD and EAC, respectively. Finally, we applied this knowledge to identify high-risk Barrett's esophagus in a new non-endoscopic test. In conclusion, mutations in EAC driver genes generally occur exceptionally early in disease development with profound implications for diagnostic and therapeutic strategies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Weaver</LastName>
                    <ForeName>Jamie M J</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Medical Research Council (MRC) Cancer Unit, University of Cambridge, Cambridge, UK. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ross-Innes</LastName>
                    <ForeName>Caryn S</ForeName>
                    <Initials>CS</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Medical Research Council (MRC) Cancer Unit, University of Cambridge, Cambridge, UK. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shannon</LastName>
                    <ForeName>Nicholas</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lynch</LastName>
                    <ForeName>Andy G</ForeName>
                    <Initials>AG</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Forshew</LastName>
                    <ForeName>Tim</ForeName>
                    <Initials>T</Initials>
                    <Identifier Source="ORCID">0000000320937020</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barbera</LastName>
                    <ForeName>Mariagnese</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Research Council (MRC) Cancer Unit, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murtaza</LastName>
                    <ForeName>Muhammed</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ong</LastName>
                    <ForeName>Chin-Ann J</ForeName>
                    <Initials>CA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Research Council (MRC) Cancer Unit, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lao-Sirieix</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Research Council (MRC) Cancer Unit, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dunning</LastName>
                    <ForeName>Mark J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Research Council (MRC) Cancer Unit, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Mike L</ForeName>
                    <Initials>ML</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Anderson</LastName>
                    <ForeName>Charlotte L</ForeName>
                    <Initials>CL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carvalho</LastName>
                    <ForeName>Benilton</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Donovan</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Underwood</LastName>
                    <ForeName>Timothy J</ForeName>
                    <Initials>TJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Sciences Division, University of Southampton, Southampton, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>May</LastName>
                    <ForeName>Andrew P</ForeName>
                    <Initials>AP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fluidigm Corporation, South San Francisco, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grehan</LastName>
                    <ForeName>Nicola</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Research Council (MRC) Cancer Unit, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hardwick</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oesophago-Gastric Unit, Addenbrooke's Hospital, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Davies</LastName>
                    <ForeName>Jim</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oxford Computing Laboratory, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oloumi</LastName>
                    <ForeName>Arusha</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>British Columbia Cancer Research Centre, Cancer Agency Research Centre, Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aparicio</LastName>
                    <ForeName>Sam</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>British Columbia Cancer Research Centre, Cancer Agency Research Centre, Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caldas</LastName>
                    <ForeName>Carlos</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eldridge</LastName>
                    <ForeName>Matthew D</ForeName>
                    <Initials>MD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Edwards</LastName>
                    <ForeName>Paul A W</ForeName>
                    <Initials>PA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosenfeld</LastName>
                    <ForeName>Nitzan</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tavaré</LastName>
                    <ForeName>Simon</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fitzgerald</LastName>
                    <ForeName>Rebecca C</ForeName>
                    <Initials>RC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Research Council (MRC) Cancer Unit, University of Cambridge, Cambridge, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>OCCAMS Consortium</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>05/12/01</GrantID>
                    <Agency>Department of Health</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>11906</GrantID>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>12088</GrantID>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>14545</GrantID>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>15874</GrantID>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>19556</GrantID>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>A12770</GrantID>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>G1002565</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MC_U105365007</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>MC_UU_12022/2</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>NF-SI-0611-10065</GrantID>
                    <Agency>Department of Health</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>NIHR-RP-02-12-011</GrantID>
                    <Agency>Department of Health</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>06</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <SupplMeshList>
            <SupplMeshName Type="Disease" UI="C562730">Adenocarcinoma Of Esophagus</SupplMeshName>
        </SupplMeshList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2014 Jan 16;33(3):347-57</RefSource>
                <PMID Version="1">23318448</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Sci Transl Med. 2013 Jul 31;5(196):196cm6</RefSource>
                <PMID Version="1">23903752</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2013 Aug;145(2):273-6</RefSource>
                <PMID Version="1">23806540</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2013 Aug;145(2):312-9.e1</RefSource>
                <PMID Version="1">23673354</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2001 Jun 1;61(11):4311-4</RefSource>
                <PMID Version="1">11389050</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Surg Endosc. 2002 Apr;16(4):671-3</RefSource>
                <PMID Version="1">11972212</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1976 Oct 1;194(4260):23-8</RefSource>
                <PMID Version="1">959840</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1988 Sep 1;319(9):525-32</RefSource>
                <PMID Version="1">2841597</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2006 Apr;38(4):468-73</RefSource>
                <PMID Version="1">16565718</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4283-8</RefSource>
                <PMID Version="1">18337506</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2009 Jul 15;25(14):1754-60</RefSource>
                <PMID Version="1">19451168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2009 Aug 15;25(16):2078-9</RefSource>
                <PMID Version="1">19505943</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 2009 Nov;58(11):1451-9</RefSource>
                <PMID Version="1">19651633</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2009 Nov 1;25(21):2865-71</RefSource>
                <PMID Version="1">19561018</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2010 Feb;10(2):87-101</RefSource>
                <PMID Version="1">20094044</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Gastroenterol. 2010 Jul;105(7):1523-30</RefSource>
                <PMID Version="1">20461069</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMJ. 2010;341:c4372</RefSource>
                <PMID Version="1">20833740</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2010 Oct 8;330(6001):228-31</RefSource>
                <PMID Version="1">20826764</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 2011 Mar;17(3):297-303</RefSource>
                <PMID Version="1">21383744</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 2011 Jul 6;103(13):1049-57</RefSource>
                <PMID Version="1">21680910</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 2011 Oct;60(10):1317-26</RefSource>
                <PMID Version="1">21478220</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Oct;43(10):964-8</RefSource>
                <PMID Version="1">21892161</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Dec;43(12):1219-23</RefSource>
                <PMID Version="1">22037554</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Jan 19;481(7381):306-13</RefSource>
                <PMID Version="1">22258609</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2012 Jan 17;21(1):36-51</RefSource>
                <PMID Version="1">22264787</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2012 Feb 1;28(3):311-7</RefSource>
                <PMID Version="1">22155872</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2012 Mar;142(3):435-441.e2</RefSource>
                <PMID Version="1">22266150</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Res. 2012 Mar;22(3):568-76</RefSource>
                <PMID Version="1">22300766</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2012 Mar 8;366(10):883-92</RefSource>
                <PMID Version="1">22397650</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2012 May 25;149(5):994-1007</RefSource>
                <PMID Version="1">22608083</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2012 May 25;149(5):979-93</RefSource>
                <PMID Version="1">22608084</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Sci Transl Med. 2012 May 30;4(136):136ra68</RefSource>
                <PMID Version="1">22649089</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Jun 21;486(7403):395-9</RefSource>
                <PMID Version="1">22495314</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Jul;44(7):760-4</RefSource>
                <PMID Version="1">22634756</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2012 Sep 1;72(17):4383-93</RefSource>
                <PMID Version="1">22751462</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Discov. 2012 Oct;2(10):899-905</RefSource>
                <PMID Version="1">22877736</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Sci Transl Med. 2013 Jan 9;5(167):167ra4</RefSource>
                <PMID Version="1">23303603</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2013 Mar 28;368(13):1199-209</RefSource>
                <PMID Version="1">23484797</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 May;45(5):478-86</RefSource>
                <PMID Version="1">23525077</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):453</RefSource>
                <PMID Version="1">25023036</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Rev Clin Oncol. 2014 Aug;11(8):439</RefSource>
                <PMID Version="1">25027592</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Genet. 2014 Aug;46(8):806-7</RefSource>
                <PMID Version="1">25070798</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Genet. 2014 Aug;46(8):806-7</RefSource>
                <PMID Version="1">25215370</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001471">Barrett Esophagus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D063646">Carcinogenesis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004938">Esophageal Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055106">Genome-Wide Association Study</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011230">Precancerous Conditions</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">EMS58861</OtherID>
        <OtherID Source="NLM">PMC4116294</OtherID>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Hayes</LastName>
                <ForeName>Stephen J</ForeName>
                <Initials>SJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yeng</LastName>
                <ForeName>Ang</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lydon</LastName>
                <ForeName>Anne-Marie</ForeName>
                <Initials>AM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dharmaprasad</LastName>
                <ForeName>Soney</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Greer</LastName>
                <ForeName>Sandra</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Preston</LastName>
                <ForeName>Shaun</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Oakes</LastName>
                <ForeName>Sarah</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Save</LastName>
                <ForeName>Vicki</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Paterson-Brown</LastName>
                <ForeName>Simon</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tucker</LastName>
                <ForeName>Olga</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Alderson</LastName>
                <ForeName>Derek</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Taniere</LastName>
                <ForeName>Philippe</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kelly</LastName>
                <ForeName>Jamie</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Byrne</LastName>
                <ForeName>James</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sharland</LastName>
                <ForeName>Donna</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Holling</LastName>
                <ForeName>Nina</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Boulter</LastName>
                <ForeName>Lisa</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Noble</LastName>
                <ForeName>Fergus</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stacey</LastName>
                <ForeName>Bernard</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crichton</LastName>
                <ForeName>Charles</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barr</LastName>
                <ForeName>Hugh</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shepherd</LastName>
                <ForeName>Neil</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Almond</LastName>
                <ForeName>L Max</ForeName>
                <Initials>LM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Old</LastName>
                <ForeName>Oliver</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lagergren</LastName>
                <ForeName>Jesper</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gossage</LastName>
                <ForeName>James</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Davies</LastName>
                <ForeName>Andrew</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mason</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chang</LastName>
                <ForeName>Fuju</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zylstra</LastName>
                <ForeName>Janine</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sanders</LastName>
                <ForeName>Grant</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wheatley</LastName>
                <ForeName>Tim</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Berrisford</LastName>
                <ForeName>Richard</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bracey</LastName>
                <ForeName>Tim</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Harden</LastName>
                <ForeName>Catherine</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bunting</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Roques</LastName>
                <ForeName>Tom</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nobes</LastName>
                <ForeName>Jenny</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Loo</LastName>
                <ForeName>Suat</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lewis</LastName>
                <ForeName>Mike</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cheong</LastName>
                <ForeName>Ed</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Priest</LastName>
                <ForeName>Oliver</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Parsons</LastName>
                <ForeName>Simon L</ForeName>
                <Initials>SL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Soomro</LastName>
                <ForeName>Irshad</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kaye</LastName>
                <ForeName>Philip</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Saunders</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pang</LastName>
                <ForeName>Vincent</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Welch</LastName>
                <ForeName>Neil T</ForeName>
                <Initials>NT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Catton</LastName>
                <ForeName>James A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Duffy</LastName>
                <ForeName>John P</ForeName>
                <Initials>JP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ragunath</LastName>
                <ForeName>Krish</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lovat</LastName>
                <ForeName>Laurence</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Haidry</LastName>
                <ForeName>Rehan</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Miah</LastName>
                <ForeName>Haroon</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kerr</LastName>
                <ForeName>Sarah</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Eneh</LastName>
                <ForeName>Victor</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Butawan</LastName>
                <ForeName>Rommel</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Igali</LastName>
                <ForeName>Laszlo</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ford</LastName>
                <ForeName>Hugo</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gilligan</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Safranek</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hindmarsh</LastName>
                <ForeName>Andy</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sudjendran</LastName>
                <ForeName>Vijayendran</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Metz</LastName>
                <ForeName>Andy</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Carroll</LastName>
                <ForeName>Nick</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Scott</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cluroe</LastName>
                <ForeName>Alison</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Miremadi</LastName>
                <ForeName>Ahmad</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mahler-Araujo</LastName>
                <ForeName>Betania</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Knight</LastName>
                <ForeName>Olga</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nutzinger</LastName>
                <ForeName>Barbara</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Peters</LastName>
                <ForeName>Chris</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abdullahi</LastName>
                <ForeName>Zarah</ForeName>
                <Initials>Z</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Debriram-Beecham</LastName>
                <ForeName>Irene</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Malhotra</LastName>
                <ForeName>Shalini</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crawte</LastName>
                <ForeName>Jason</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>MacRae</LastName>
                <ForeName>Shona</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Noorani</LastName>
                <ForeName>Ayesha</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Elliott</LastName>
                <ForeName>Rachael Fels</ForeName>
                <Initials>RF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Li</LastName>
                <ForeName>Xiaodun</ForeName>
                <Initials>X</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bower</LastName>
                <ForeName>Lawrence</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Achilleos</LastName>
                <ForeName>Achilleas</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bornschein</LastName>
                <ForeName>Jan</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zeki</LastName>
                <ForeName>Sebastian</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chettouh</LastName>
                <ForeName>Hamza</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Secrier</LastName>
                <ForeName>Maria</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>de Silva</LastName>
                <ForeName>Nadeera</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gregson</LastName>
                <ForeName>Eleanor</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yang</LastName>
                <ForeName>Tsun-Po</ForeName>
                <Initials>TP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Neil</LastName>
                <ForeName>J Robert</ForeName>
                <Initials>JR</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>1</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.3013</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.3013</ArticleId>
            <ArticleId IdType="pubmed">24952744</ArticleId>
            <ArticleId IdType="pmc">PMC4116294</ArticleId>
            <ArticleId IdType="mid">EMS58861</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1221947</PMID>
        <DateCreated>
            <Year>1976</Year>
            <Month>06</Month>
            <Day>02</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1976</Year>
            <Month>06</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-4967</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>34</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1975</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of the rheumatic diseases</Title>
                <ISOAbbreviation>Ann. Rheum. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Penicillamine nephropathy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>544</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Swinson</LastName>
                    <ForeName>D R</ForeName>
                    <Initials>DR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamilton</LastName>
                    <ForeName>E E</ForeName>
                    <Initials>EE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dische</LastName>
                    <ForeName>F E</ForeName>
                    <Initials>FE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Ann Rheum Dis</MedlineTA>
            <NlmUniqueID>0372355</NlmUniqueID>
            <ISSNLinking>0003-4967</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>GNN1DV99GX</RegistryNumber>
                <NameOfSubstance UI="D010396">Penicillamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007678">Kidney Glomerulus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010396">Penicillamine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011507">Proteinuria</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1006486</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1975</Year>
                <Month>12</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1975</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1975</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1221947</ArticleId>
            <ArticleId IdType="pmc">PMC1006486</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">24854284</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7786</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>219</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>5</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chemico-biological interactions</Title>
                <ISOAbbreviation>Chem. Biol. Interact.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Design, synthesis and characterization of zinc-morin, a metal flavonol complex and evaluation of its antidiabetic potential in HFD-STZ induced type 2 diabetes in rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>9-17</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cbi.2014.05.003</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0009-2797(14)00161-6</ELocationID>
            <Abstract>
                <AbstractText>The present study deals with the synthesis, characterization of zinc-morin complex and evaluation of its antidiabetic efficacy in High Fat Diet (HFD)-fedStreptozotocin (STZ) induced diabetic rats. Oral administration of zinc-morin complex to diabetic rats (5mg/kg body weight/day) for a period of 30 days resulted in the decreased levels of blood glucose and HbA1c. Oral administrations of the zinc-morin complex for 30 days significantly improved hyperglycemia, glucose intolerance, and insulin resistance. The elevated levels of lipid peroxides declined and the antioxidant competence was found to be improved in diabetic rats treated with the complex. The status of the lipid and lipoprotein profile in the serum was normalized upon treatment. Levels of TNFα decreased upon treatment with the complex. The altered levels of adipokines such as adiponectin and leptin were normalized upon treatment with the complex. In conclusion, the present study indicates that the zinc-morin complex possesses antidiabetic, antidyslipidemic and antioxidant potentials in HFD-fedSTZ induced diabetic rats.</AbstractText>
                <CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sendrayaperumal</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, University of Madras, Guindy Campus, Chennai 600 025, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iyyam Pillai</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Inorganic Chemistry, University of Madras, Guindy Campus, Chennai 600 025, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Subramanian</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, University of Madras, Guindy Campus, Chennai 600 025, India. Electronic address: subbus2020@yahoo.co.in.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Chem Biol Interact</MedlineTA>
            <NlmUniqueID>0227276</NlmUniqueID>
            <ISSNLinking>0009-2797</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Antidiabetic</Keyword>
            <Keyword MajorTopicYN="N">Antidyslipidemic</Keyword>
            <Keyword MajorTopicYN="N">Antioxidant</Keyword>
            <Keyword MajorTopicYN="N">High fat</Keyword>
            <Keyword MajorTopicYN="N">Insulin resistance</Keyword>
            <Keyword MajorTopicYN="N">Zinc–Morin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24854284</ArticleId>
            <ArticleId IdType="pii">S0009-2797(14)00161-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cbi.2014.05.003</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18468624</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>10</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>01</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0022-3956</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>43</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of psychiatric research</Title>
                <ISOAbbreviation>J Psychiatr Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Restless legs syndrome as side effect of second generation antidepressants.</ArticleTitle>
            <Pagination>
                <MedlinePgn>70-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2008.02.006</ELocationID>
            <Abstract>
                <AbstractText>Although of clinical interest, the question is still not fully answered whether antidepressants (AD) can cause or exacerbate restless legs syndrome (RLS). The literature provides contradictory information. This study addresses this problem for the class of second generation AD. In four neurological offices, all patients treated for the first time with an AD were prospectively observed with regard to the question of whether RLS occurred or pre-existing RLS worsened as a result of the medication. Because initial treatment in the participating offices is mainly executed with &quot;modern&quot; selective AD, the study was restricted to these drugs (fluoxetine, paroxetine, citalopram, sertraline, escitalopram, venlafaxine, duloxetine, reboxetine, and mirtazapine). In 9% of patients, RLS was recorded as a side effect related to the administration of AD. The frequency of this side effect varied among the drugs. The problem is most pronounced with mirtazapine provoking or deteriorating RLS in 28% of patients. By contrast, no case occurred during use of reboxetine. As for the other AD, the rate of newly occurred and deteriorated RLS, ranged from 5% to 10%. Typically, RLS occurred during the initial days of treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rottach</LastName>
                    <ForeName>Klaus G</ForeName>
                    <Initials>KG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hafenmarkt 12, 87600 Kaufbeuren, Germany. Klaus.Rottach@t-online.de</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schaner</LastName>
                    <ForeName>Bernhard M</ForeName>
                    <Initials>BM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kirch</LastName>
                    <ForeName>Michael H</ForeName>
                    <Initials>MH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zivotofsky</LastName>
                    <ForeName>Ari Z</ForeName>
                    <Initials>AZ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teufel</LastName>
                    <ForeName>Lydia M</ForeName>
                    <Initials>LM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gallwitz</LastName>
                    <ForeName>Thorsten</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Messer</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>05</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Psychiatr Res</MedlineTA>
            <NlmUniqueID>0376331</NlmUniqueID>
            <ISSNLinking>0022-3956</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0DHU5B8D6V</RegistryNumber>
                <NameOfSubstance UI="D015283">Citalopram</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>250PJI13LM</RegistryNumber>
                <NameOfSubstance UI="D008803">Mianserin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>947S0YZ36I</RegistryNumber>
                <NameOfSubstance UI="C074679">reboxetine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>A051Q2099Q</RegistryNumber>
                <NameOfSubstance UI="C035133">mirtazapine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000928">Antidepressive Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015283">Citalopram</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003866">Depressive Disorder</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003865">Depressive Disorder, Major</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008803">Mianserin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009025">Morpholines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012148">Restless Legs Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017367">Serotonin Uptake Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2007</Year>
                <Month>7</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>1</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0022-3956(08)00052-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jpsychires.2008.02.006</ArticleId>
            <ArticleId IdType="pubmed">18468624</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18263716</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>04</Month>
            <Day>02</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>05</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0363-6135</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>294</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Heart and circulatory physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Heart Circ. Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The intestine as source of cytotoxic mediators in shock: free fatty acids and degradation of lipid-binding proteins.</ArticleTitle>
            <Pagination>
                <MedlinePgn>H1779-92</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpheart.00902.2007</ELocationID>
            <Abstract>
                <AbstractText>Shock and multiple organ failure remain primary causes of late-stage morbidity and mortality in victims of trauma. During shock, the intestine is subject to extensive cell death and is the source of inflammatory factors that cause multiorgan failure. We (34) showed previously that ischemic, but not nonischemic, small intestines and pancreatic protease digested homogenates of normal small intestine can generate cytotoxic factors capable of killing naive cells within minutes. Using chloroform/methanol separation of rat small intestine homogenates into lipid fractions and aqueous and sedimented protein fractions and measuring cell death caused by those fractions, we found that the cytotoxic factors are lipid in nature. Recombining the lipid fraction with protein fractions prevented cell death, except when homogenates were protease digested. Using a fluorescent substrate, we found high levels of lipase activity in intestinal homogenates and cytotoxic levels of free fatty acids. Addition of albumin, a lipid binding protein, prevented cell death, unless the albumin was previously digested with protease. Homogenization of intestinal wall in the presence of the lipase inhibitor orlistat prevented cell death after protease digestion. In vivo, orlistat plus the protease inhibitor aprotinin, administered to the intestinal lumen, significantly improved survival time compared with saline in a splanchnic arterial occlusion model of shock. These results indicate that major cytotoxic mediators derived from an intestine under in vitro conditions are free fatty acids. Breakdown of free fatty acid binding proteins by proteases causes release of free fatty acids to act as powerful cytotoxic mediators.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Penn</LastName>
                    <ForeName>Alexander H</ForeName>
                    <Initials>AH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dept. of Bioengineering, The Whitaker Institute for Biomedical Engineering, University of California, San Diego, La Jolla, CA 92093-0412, USA. apenn@bioeng.ucsd.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmid-Schönbein</LastName>
                    <ForeName>Geert W</ForeName>
                    <Initials>GW</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>HL67825</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>02</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Physiol Heart Circ Physiol</MedlineTA>
            <NlmUniqueID>100901228</NlmUniqueID>
            <ISSNLinking>0363-6135</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050556">Fatty Acid-Binding Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005230">Fatty Acids, Nonesterified</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007783">Lactones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012710">Serum Albumin, Bovine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014020">Tissue Extracts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9087-70-1</RegistryNumber>
                <NameOfSubstance UI="D007611">Aprotinin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>95M8R751W8</RegistryNumber>
                <NameOfSubstance UI="C055122">orlistat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.1.3</RegistryNumber>
                <NameOfSubstance UI="D008049">Lipase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.-</RegistryNumber>
                <NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007611">Aprotinin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D048430">Cell Shape</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004791">Enzyme Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050556">Fatty Acid-Binding Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005230">Fatty Acids, Nonesterified</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007421">Intestine, Small</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007511">Ischemia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007783">Lactones</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008049">Lipase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009504">Neutrophils</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010179">Pancreas</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010447">Peptide Hydrolases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011480">Protease Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012710">Serum Albumin, Bovine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012769">Shock</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014020">Tissue Extracts</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>30</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">00902.2007</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpheart.00902.2007</ArticleId>
            <ArticleId IdType="pubmed">18263716</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
